Você procurou por: single arm, randomized, multicenter study (Inglês - Sueco)

single center multicenter study
enkelcenter

multicenter study
multicenterstudie

single-arm phase 2 study (ca209063)
enarmad fas 2-studie (ca209063)

mantle cell lymphoma single arm phase ii study
enarmad fas ii-studie på mantelcellslymfom

study 304 was a single-arm, open-label, multicenter study of cerdelga in 26 patients.
studie 304 var en öppen multicenterstudie med en behandlingsarm där 26 patienter behandlades med cerdelga.

an open-label, single-arm, multicenter study was conducted in patients intolerant or resistant to imatinib.
en öppen, enarmad, multicenterstudie genomfördes med patienter som var intoleranta eller resistenta mot imatinib.

the study was an open-label, single arm, non-randomized design.
studien hade en öppen, enarmad, icke-randomiserad utformning.

crystal was a single-arm study with 0.5 mg ranibizumab monotherapy.
crystal var en enkelarmad studie med 0,5 mg ranibizumab monoterapi.

squire, a global, multicenter, two-arm, randomized study of portrazza, was conducted in
squire, en global, randomiserad multicenterstudie av portrazza med två armar utfördes på

9 study 2 was a randomized, controlled, multicenter study comparing the zevalin therapeutic regimen to treatment with rituximab.
studie 2 var en randomiserad, kontrollerad multicenterstudie, som jämförde en behandlingsregim med zevalin med rituximab- behandling.

single-arm open-label studies
enarmade, öppna studier

efficacy in phase ii sprycel single-arm
16 effekt i enarmade fas- ii- prövningar med sprycela tabell 5:

blincyto was evaluated in an open-label, multicentre, single-arm phase ii study of 189 patients.
blincyto utvärderades i en öppen, multicenter, enarmad fas ii -studie med 189 patienter.

study 1 was a single arm study of 54 patients with relapsed follicular lymphoma refractory to rituximab treatment.
studie 1 var en icke- jämförande studie med 54 patienter med recidiverande follikulärt lymfom, refraktärt mot rituximab- behandling.

multicenter studies as topic
multicenterstudier, principer

study 1 was a single-arm study of 54 patients with relapsed follicular lymphoma refractory to rituximab treatment.
studie 1 var en icke-jämförande studie med 54 patienter med recidiverat follikulärt lymfom, refraktärt mot rituximab-behandling.

the mah focused the discussion on the pivotal randomized phase 3 study jhqj, and the main supportive single-arm phase 2 study jhrw.
innehavaren av godkännandet för försäljning fokuserade diskussionen på den pivotala randomiserade fas 3- studien jhqj och på den mest betydande stödjande studien, den enarmade fas 2- studien jhrw.

an open-label, single-arm, multicenter study was conducted in patients with lymphoid blast phase cml or ph+ all who were resistant or intolerant to prior imatinib therapy.
en öppen, enarmad, multicenterstudie genomfördes hos patienter med kml i lymfoid blastkris eller ph+ all, som var resistenta eller intoleranta mot tidigare imatinib- behandling.

hiv-positive, paediatric patients, aged 2 through 18 years, were studied in a randomized, open-label, multicenter study (trial 1182.14).
hiv-positiva, pediatriska patienter, i åldern 2 till 18 år, studerades i en randomiserad, öppen multicenterstudie (studie 1182.14).

the immunogenicity of prevenar has been investigated in an open-label, multicenter study in 49 infants with sickle cell disease.
immunogenicitetsdata för prevenar har studerats i en öppen, multicenter studie på 49 barn med sickle- cell anemi.